Cost-Effectiveness of Interventions to Prevent HIV and STDs Among Women: A Randomized Controlled Trial

AIDS and Behavior

Volumn 18, Issue 10, 2014, Pages 1913-1923

  Ruger, Jennifer Prah ^a   Abdallah, Arbi Ben ^b   Ng, Nora Y ^c   Luekens, Craig ^c   Cottler, Linda ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Bernoullian model; Cost effectiveness; HIV; STDs; Substance abuse

Indexed keywords

ADULT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HIV SEROPOSITIVITY; HUMAN; PATIENT EDUCATION; PREVENTION AND CONTROL; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; SEXUALLY TRANSMITTED DISEASES; SUBSTANCE ABUSE; SUBSTANCE-RELATED DISORDERS; TRANSMISSION; VAGINA SMEAR; WOMEN'S HEALTH;

ADULT; COST-BENEFIT ANALYSIS; FEMALE; HIV SEROPOSITIVITY; HUMANS; PATIENT EDUCATION AS TOPIC; PREVENTIVE HEALTH SERVICES; PUBLIC HEALTH; SEXUALLY TRANSMITTED DISEASES; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS; VAGINAL SMEARS; WOMEN'S HEALTH;

EID: 84919480775     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-014-0745-8     Document Type: Article

References (35)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–14.
2. Australian Commonwealth Department of Health and Ageing. 2002. Return on investment in needle and syringe programs in Australia. Available at http://www.health.gov.au/internet/main/publishing.nsf/Content/2C9410E4A867F2EBCA257650000077B9/$File/roirep.pdf. Accessed 22 Feb 2012.
3. Branson BM, Peterman TA, Cannon RO, Ransom R, Zaidi AA. Group counseling to prevent sexually transmitted disease and HIV: a randomized controlled trial. Sex Transm Dis. 1998;25:553–60.
4. Centers for Disease Control and Prevention. 2007. HIV prevalence among selected populations: high-risk populations. Available at http://www.cdc.gov/hiv/topics/testing/resources/reports/hiv_prevalence/high-risk.htm. Accessed 22 Feb 2012.
5. Chesson HW, Collins D, Koski K. Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States. Cost Eff Res Alloc. 2008;6:10.
6. Chesson HW, Greenberg JB, Hennessy M. The cost-effectiveness of the WINGS intervention: a program to prevent HIV and sexually transmitted diseases among high-risk urban women. BMC Infect Dis. 2002;2:24.
7. Chesson HW, Pinkerton SD. Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions. J Acquir Immune Defic Syndr. 2000;24:48–56.
8. City of St. Louis Department of Health. 2005. Program monitoring. Available at http://stlouis.missouri.org/citygov/health/pdf/cd/CDDec2005.pdf Accessed 22 Sep 2010.
9. City of St. Louis Department of Health. 2007. Public Health: Understanding Our Needs. St. Louis. Available at http://stlouis-mo.gov/government/departments/health/documents/upload//UON_VOL_3_20072.pdf.Accessed 22 Feb 2012.
10. Diaz A, Junquera ML, Esteban V, Martínez B, Pueyo I, Suarez J, STI Study Group and EPI-VIH Group. HIV/STI co-infection among men who have sex with men in Spain. Euro Surveill. 2009;14, pii 19426.
11. Dionne-Odom J, Osborn MK, Radziewicz H, Grakoui A, Workowski K. Acute hepatitis C and HIV coinfection. Lancet Infect Dis. 2009;9:775–83.
12. Farnham PG, Holtgrave DR, Gopalappa C, Hutchinson AB, Sansom SL. Lifetime costs and quality-adjusted life years saved from HIV prevention in the test and treat era. J Acquir Immune Defic Syndr. 2013;64:e15–8.
13. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
14. Kamb ML, Fishbein M, Douglas JM Jr, Rhodes F, Rogers J, Bolan G, Peterman TA. Efficacy of risk-reduction counseling to prevention human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT study group. J Am Med Assoc. 1998;280:1161–7.
15. Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med. 1997;336:1097–100.
16. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ. 2000;9:623–30.
17. Onen NF, Shacham E, Stamm KE, Overton ET. Comparisons of sexual behaviors and STD prevalence among older and younger individuals with HIV infection. AIDS Care. 2010;22:711–7.
18. Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med. 1997;44:1303–12.
19. Pinkerton SD, Abramson PR. The Bernoulli-process model of HIV transmission: applications and implications. In: Holtgrave DR, editor. Handbook of economic evaluation of HIV prevention programs. New York: Plenum Press; 1998. p. 13–32.
20. Pinkerton SD, Holtgrave DR. A method for evaluating the economic efficiency of HIV behavioral risk reduction interventions. AIDS Behav. 1998;2:189–201.
21. Pinkterton SD, Holtgrave DR, Leviton LC, Wagstaff DA, Abramsom PR. Model-based evaluation of HIV prevention interventions. Eval Rev. 1998;22:155–74.
22. Pinkterton SD, Johnson-Masotti AP, Otto-Salaj LL, Stevenson LY, Hoffman RG. Cost-effectiveness of an HIV prevention intervention for mentally ill adults. Mental Health Serv Res. 2001;3:45–55.
23. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med. 2004;164:46–54.
24. Resch S, Altice FL, Paltiel AD. Cost-effectiveness of HIV screening for incarcerated pregnant women. J Acquir Immune Defic Syndr. 2005;38:163–73.
25. Ruger JP, Abdallah AB, Cottler L. Costs of HIV prevention among out-of-treatment drug-using women: results of a randomized controlled trial. Public Health Rep. 2010;125(suppl 1):83–94.
26. Ruger JP, Lazar CM. Economic evaluation of drug abuse treatment and HIV prevention programs in pregnant women: a systematic review. Addict Behav. 2012;37(1):1–10.
27. Ruger JP, Abdallah AB, Luekens C, Cottler L. Cost-effectiveness of peer-delivered interventions for cocaine and alcohol abuse among women: a randomized controlled trial. PLoS One. 2012;7:e33594.
28. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. J Am Med Assoc. 2003;290:228–37.
29. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Freedberg KA. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44:990–7.
30. Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med. 2001;111:614–21.
31. Tempalski B, Lieb S, Cleland CM, Cooper H, Brady JE, Friedman SR. HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992–2002. J Urban Health. 2009;86:132–54.
32. Verucchi G, Calza L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection. 2004;32:33–46.
33. Wilson DP, Heymer KJ, Anderson J, O’Connor J, Harcourt C, Donovan B. Sex workers can be screened too often: a cost-effectiveness analysis in Victoria, Australia. Sex Transm Infec. 2010;86:117–25.
34. World Health Organization. Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. Geneva: World Health Organization Department of HIV/AIDS; 2001.
35. World Health Organization. Global Alert and Response. Geneva: World Health Organization. Hepatitis C; 2002.